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A Leishmania donovani species-specific monoclonal antibody (monoclonal antibody D2) was evaluated for its
diagnostic and prognostic potential by a competitive enzyme-linked immunosorbent assay (C-ELISA) in sera
from Indian patients with visceral leishmaniasis (VL) and seven patients with post-kala-azar dermal leish-
maniasis (PKDL). These results were compared with those obtained by microscopy with Giemsa-stained tissue
smears and a direct enzyme-linked immunosorbent assay (direct ELISA) with crude parasite antigen. Of 121
patients with clinically diagnosed VL examined, 103 (85.1%) were positive and 11 (9.1%) were negative by all
three methods. An additional 7 (5.8%) who were negative by microscopy were positive by both C-ELISA and
direct ELISA. Seven PKDL patients were also examined and were found to be positive by all three methods.
Analysis of the chemotherapeutic response to sodium antimony gluconate of these 110 serologically positive VL
patients showed that 57 (51.8%) were drug responsive and 53 (48.2%) were drug resistant. The C-ELISA with
sera from 20 longitudinally monitored VL patients before and after chemotherapy showed a significant de-
crease in percent inhibition of monoclonal antibody D2 in drug-responsive patients. However, in drug-unre-
sponsive patients, the percent inhibition of D2 was unchanged or was slightly increased. Our results therefore
indicate (i) the applicability of L. donovani species-specific monoclonal antibody D2 for sensitive and specific
serodiagnosis by C-ELISA, (ii) that the C-ELISA is more sensitive than microscopy, especially for early diag-
nosis, (iii) that L. donovani is still the main causative agent of VL, irrespective of the chemotherapeutic
response, and (iv) that the C-ELISA can be used to evaluate the success of drug treatment.
Visceral leishmaniasis (VL) or kala-azar is a major public
health problem in eastern India, where it is endemic and where
every 10 to 15 years it assumes epidemic proportions (5). In
1993, 30 districts in Bihar Province with a target population of
71.4 million were seriously affected (23). In the present epi-
demic (early 1990s to date), the incidence of unresponsiveness
to antimonials has increased dramatically to over 60% (21),
whereas it was only 8.6% in the epidemic that occurred in the
early 1980s (22).
Considering the cyclical reemergence of the disease, a vital
aspect of disease control is early diagnosis. The “gold stan-
dard” for diagnosis is still the direct demonstration of the
Leishmania parasite in Giemsa-stained smears from tissue as-
pirates. However, due to the insensitivity of this method (1)
coupled with the potential risks of the procedure, most patients
in rural areas are empirically treated.
High titers of specific and nonspecific antibodies are a hall-
mark of patients presenting with kala-azar. This has allowed
the development of several antibody-based serological tests in
India, namely, the direct agglutination test (DAT) (17), indi-
rect immunofluorescence (3), antigen detection (19), and the
enzyme-linked immunosorbent assay (ELISA) (4, 6, 13). These
tests have yet to gain widespread acceptability due to cross-
reactivity with specimens from patients with coendemic dis-
eases or antigen instability in the case of DAT (15). Intro-
duction of PCR has obviated these problems (20), but its
application as a routine diagnostic method has been limited by
the mandatory technical expertise and equipment required. A
major failing with most diagnostic methods presently available
in India is their inability to identify the parasite species. In light
of the increasing incidence of unresponsiveness of patients
with VL and post-kala-azar dermal leishmaniasis (PKDL) to
antimonial treatment in the current epidemic (1990s to date)
and recent reports that Leishmania tropica causes VL in India
(18), a pertinent unanswered question is whether a variation in
the causative Leishmania parasite species may be responsible
for the refractoriness to treatment with antimonials. If a causal
relationship does exist, then early species identification may
provide guidelines for the modification of clinical treatment.
A previous study (10) with sera primarily from patients in
South America and Africa showed that a competitive ELISA
(C-ELISA) with species-specific monoclonal antibodies (MAbs)
directed against Leishmania donovani (MAb D2) could be
used to diagnose VL specifically. In this study we demonstrate
that the C-ELISA with MAb D2 can be used to diagnose both
specifically and sensitively Indian leishmaniasis and that it can
also be used for the prognostic evaluation of the disease and
the success of drug treatment.
MATERIALS AND METHODS
Study population. Pretreatment sera from 121 patients clinically diagnosed
with kala-azar or VL were examined. Their salient clinical features were fever of
known duration, hepatosplenomegaly, either a resident in or recent travel to a
region where kala-azar is endemic, and no prior antileishmanial treatment. On
the basis of the duration of fever, VL patients were broadly classified into the
following three groups: group A, short duration (,30 days); group B, interme-
diate duration (1 to 3 months); and group C, long duration (.3 months). PKDL
patients (n 5 7) were also included.
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A longitudinal study was also carried out. In that study serum was collected on
admission and again on completion of a single course of sodium antimony
gluconate (SAG) treatment (20 mg/kg of body weight for 4 to 6 weeks) from 20
patients with biopsy-confirmed kala-azar. On the basis of their clinical and
parasitological responses to treatment, they were grouped as either drug respon-
sive (remission of fever, regression of liver and spleen showed, and absence of
parasites in Giemsa-stained tissue smears) or drug unresponsive (persistence of
fever and hepatosplenomegaly along with persistence of parasites in Giemsa-
stained tissue smears).
Control sera (n 5 60) were obtained from patients with malaria (n 5 10),
tuberculosis (n 5 10), and leprosy (n 5 10) as well as healthy controls from both
areas of endemicity (n 5 10) and areas of nonendemicity (n 5 20).
Study design. Coded blood samples were sent to the Indian Institute of
Chemical Biology, Calcutta, India, for serodiagnosis (C-ELISA and ELISA).
Giemsa-stained biopsy smears were reviewed independently in Muzaffarpur,
Patna, and Calcutta, India, according to the recommendations of the World
Health Organization (24). The C-ELISA was initially performed with 20 speci-
mens from patients with biopsy-proven VL, i.e., microscopic demonstration of
amastigotes. Subsequently, samples were collected from patients who were clin-
ically diagnosed with VL, and on completion of the assays the results were
compared to ensure “blindness” in the protocol.
Bone marrow or splenic aspirates were routinely investigated for all patients in
this study who were clinically diagnosed with kala-azar. Informed consent was
obtained from patients or their parents and volunteers for collection of 1 ml of
peripheral blood; serum was separated from whole blood and was stored at
220°C.
MAbs. The species-specific MAbs directed against L. donovani (MAb D2) and
L. tropica (MAb T11) were prepared by fusing the NS-1 (P3-X63/Ag8) plasma-
cytoma cell line with spleen cells obtained from BALB/c mice immunized with
crude membranes of L. donovani (12) and L. tropica (11). MAb D2 reacts with
L. donovani-specific antigenic determinants of 70 and 72 kDa (9), whereas MAb
T11 recognizes an L. tropica-specific glycoconjugate corresponding to 32 to 44
kDa and also reacts with additional antigenic components of 55, 80, 92, and 130
kDa (11). Ascitic fluid containing either MAb D2 or MAb T11 was prepared by
injecting the hybridoma cell line into pristane-primed BALB/c mice and was used
in this study.
Preparation of parasite antigen. Crude parasite antigen for ELISA and C-
ELISA was prepared from an Indian L. donovani strain (MHOM/IN/83/AG83)
(2) and an L. tropica strain (MHOM/SU/74/K27) recommended for use by the
World Health Organization. Promastigotes were harvested with phosphate-buff-
ered saline (PBS), and the cell pellet was resuspended in lysis buffer (20 mM
Tris-HCl, 40 mM NaCl [pH 7.4]) containing 2 mM phenylmethylsulfonyl fluo-
ride, 1 mg of leupeptin per ml, 5 mM EDTA, and 5 mM iodoacetamide (10).
C-ELISA and ELISA. Immobilized crude Leishmania antigen prepared as
described above was used to coat 96-well flat-bottom microtiter plates (0.1
mg/ml, 50 ml/well, in 0.02 M phosphate buffer [pH 7.8]). Following an overnight
incubation, the wells were washed thrice with 0.1% Tween 20 in PBS (PBS-T; pH
7.2) washing buffer. The wells were then blocked with 2% fetal calf serum in PBS
for 8 h at 4°C. Patient serum, diluted 1:50 for C-ELISA and 1:500 for ELISA, was
incubated overnight at 4°C in duplicate and was washed with PBS-T. In the
C-ELISA, the wells were then incubated with MAb D2 or MAb T11 (dilution,
1:1,000) for 2 h at 4°C and washed with PBS-T. Binding was assayed colorimetri-
cally with either horseradish peroxidase-conjugated rabbit anti-mouse immuno-
globulin G (IgG; 1:5,000; Cappel) for C-ELISA or anti-human IgG (1:10,000;
Sigma) for ELISA and 100 ml of 2,29-azino-bis(3-ethylbenzthiazoline-6-sulfonic
acid) ammonium salt as the substrate. The optical density (OD) at 405 nm was
measured. Negative control samples from asymptomatic individuals from areas
of endemicity were included on each plate. MAb (D2 and T11) binding following
incubation of the plates with control normal human serum was equated to 100%
binding, i.e., no MAb D2 or MAb T11 inhibition. The percent MAb D2 or MAb
T11 binding of a sample was then calculated as follows: [(OD with 100% bind-
ing 2 OD of the sample)/OD with 100% binding] 3 100.
Accordingly, the percent inhibition of MAb D2 or MAb T11 binding was
extrapolated. Sera which inhibited MAb D2 or MAb T11 binding by .15% were
considered positive. This cutoff value of .15% was established on the basis of a
pilot study in which the percent inhibition of MAb D2 in 20 positive control
serum specimens (i.e., in which amastigotes were found to be present in Giemsa-
stained tissue smears) and 20 negative control serum specimens was measured.
The mean percent inhibition of MAb D2 for healthy controls was 5.2% 6 1.0%.
For ELISA, sera which gave a mean absorbance that was twice that for normal
human serum from an area of endemicity were considered positive for VL and
PKDL.
Statistical analysis. The statistical significance of the results of the longitudi-
nal study was compared by Student’s t test (paired and unpaired), and P values
of ,0.05 were considered significant.
RESULTS
This study included 208 individuals, of whom 121 were sus-
pected cases of VL, and their principal clinical data are given
in Table 1. These patients were broadly divided into three
groups according to their durations of illness. In all three
groups, the ages ranged from 3 to 40 years and the overall ratio
of males:females was 78:43, with no differences observed be-
tween the three groups. A progressive increase in spleen size
was observed with increasing duration of illness. The samples
were screened for the presence of antibodies against human
immunodeficiency virus (HIV) and were found to be negative.
Group A. Of 25 patients included in this group, 17 (68%)
were positive by microscopic examination, while 21 (84%)
were positive by serology (C-ELISA with MAb D2 inhibition
and ELISA; Table 2). All 17 smear-positive patients were
C-ELISA and ELISA positive, whereas 4 of 8 smear-negative
patients were positive by both ELISAs. The 4 (16%) additional
patients in whom VL was detected by serology did not have
false-positive results because they proved to be have VL on
therapeutic grounds. Pairwise comparison of the assays showed
84% concordance between smear and C-ELISA and 100%
concordance between ELISA and C-ELISA. Both microscopic
and serological methods were able to detect disease as early as
10 days after the first appearance of clinical symptoms. The
mean 6 standard deviation (SD) percent MAb D2 inhibition
and the absorbance at 405 nm by ELISA were 20.7% 6 9.6%
and 0.34% 6 0.18%, respectively (Table 2; Fig. 1). The four
patients who were negative by all three methods were micro-
TABLE 1. Clinical data for patients with suspected
VL included in this study
Group Patientno.
Mean 6 SD
duration of
illness
(days)
Spleen size
(cm)
No. of patients in the
indicated response
category/total no.
tested (%)a
Avg Range SAG resp. SAG resist.
A 25 19.0 6 5.3 3.7 1.5–10.0 12/21 (57.0) 9/21 (43.0)
B 43 63.1 6 19.6 6.2 3.0–12.0 18/37 (48.6) 19/37 (51.4)
C 53 187.5 6 95.0 8.4 4.5–15.0 27/52 (52.0) 25/52 (48.0)
a Patients who were ELISA positive (n 5 121) received a single course of
SAG. SAG resp., patients cured by chemotherapy; SAG resist., patients refrac-
tory to chemotherapy. Data were based on parasitological and clinical criteria
evaluated at the conclusion of treatment.
TABLE 2. Results of tissue smear examination and serological tests (ELISA and C-ELISA) for patients clinically diagnosed with VLa
Group
No. (%) of patientsb
Mean 6 SD % inhibition
of MAb D2 by C-ELISA
Mean 6 SD OD at
405 nm by ELISASmear positive,
serology positive
Smear negative,
serology negative
Smear negative,
serology positive
A (n 5 25) 17 (68.0) 4 (16.0) 4 (16.0) 20.7 6 9.6 0.36 6 0.18
B (n 5 43) 34 (79.0) 6 (14.0) 3 (7.0) 39.2 6 17.5 0.69 6 0.36
C (n 5 53) 52 (98.1) 1 (1.9) 0 (0.0) 50.8 6 13.1 0.85 6 0.24
a Sera were assayed by C-ELISA and ELISA as described in Materials and Methods.
b Smear, microscopic examination of Giemsa-stained splenic or bone marrow aspirates; serology, C-ELISA and ELISA.
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scopically confirmed to have malaria by demonstration of the
presence of Plasmodium vivax.
Group B. Group B included 43 patients with an intermediate
duration of illness (1 to 3 months); 34 (79.0%) were positive by
all three methods, and an additional 3 (7.0%) were positive by
both ELISAs. The C-ELISA detected antibodies specific for
L. donovani (MAb D2) in all smear-positive patients. Concor-
dances were 93.0% between microscopy and C-ELISA and
100% between C-ELISA and ELISA. Compared to group A,
there was a 47.2% increase in the inhibition of MAb D2 bind-
ing (mean 6 SD 5 39.2% 6 17.5%) (Fig. 1; Table 2). Simi-
larly, the mean 6 SD absorbance at 405 nm by ELISA for this
group increased by 50.7% compared to that for group A
(0.69 6 0.36) (Table 2). The six C-ELISA-negative patients
were confirmed to have tuberculosis by positive acid-fast stain-
ing of sputum specimens.
Group C. Group C consisted of 53 patients whose duration
of illness ranged from 3 months to 1 year. All 52 (98.1%)
smear-positive patients were C-ELISA (MAb D2 inhibition)
and ELISA positive, with the concordance among the three
assays being 100%. The mean 6 SD percent inhibition of MAb
D2 binding was 50.8% 6 13.1% (Fig. 1; Table 2). The level of
inhibition of MAb D2 binding in this group increased by 59.4
and 22.8% compared to those for group A and group B, re-
spectively. The mean 6 SD absorbance at 405 nm by ELISA
was 0.85 6 0.24; this was an increase of 60.0 and 19.0% com-
pared to those for group A and group B, respectively (Table 2).
A single patient who was negative by all three methods was
diagnosed with hypersplenism of unknown etiology.
Evaluation by C-ELISA of drug responsiveness in kala-azar
patients. The inhibition of MAb D2 binding was measured in
20 VL patients pre- and posttreatment. Ten patients respond-
ed to drug treatment, whereas 10 were drug unresponsive. In
the drug-responsive group the mean 6 SD percent D2 inhibi-
tion decreased from 43.0% 6 18.2% to 20.0% 6 20.0% (P ,
0.05) (Fig. 2, group A). This correlated with the observed re-
ductions in their parasite loads. Conversely, in VL patients
who were drug unresponsive, their mean 6 SD percent MAb
D2 inhibition increased from 46.7% 6 17.0% to 50.2% 6 6.3%
(Fig. 2, group B).
PKDL patients. Seven patients were microscopically con-
firmed to have PKDL, and the mean 6 SD percent MAb D2
inhibition for these patients was 26.6% 6 5.3% (range, 18 to
34%).
Binding with L. tropica-directed MAb T11. The binding of
MAb T11, when it was tested in conjunction with serum sam-
ples from patients with leishmaniasis, was negligible. The
mean 6 SD percentages of MAb T11 inhibition were 5.3% 6
0.8% and 4.6% 6 1.0% for sera from VL and PKDL patients,
respectively.
Correlation between C-ELISA and ELISA. A strong positive
correlation between individual antileishmanial antibody titers
as measured by ELISA and the percent inhibition of MAb D2
binding as measured by C-ELISA was obtained (r2 5 0.84)
(Fig. 3).
Chemotherapeutic response to SAG. All patients with clin-
ically diagnosed VL included in this study had not received any
prior antileishmanial treatment, and serum was collected prior
to pentavalent antimonial treatment. All 110 ELISA-positive
patients received a single course of SAG treatment, and on its
completion, their chemotherapeutic responses were clinically
and parasitologically assessed. They were considered SAG re-
sponsive (remission of fever, showed regression of liver and
spleen, and absence of parasites in Giemsa-stained tissue
FIG. 1. Percent inhibition of binding of L. donovani-specific MAb D2 by sera
from Indian VL patients increases with duration of illness. Patients were divided
into three groups on the basis of the length of time that clinical symptoms were
apparent: group A, ,30 days; group B, 1 to 3 months; and group C, 3 to 12
months.
FIG. 2. Percent inhibition of binding of L. donovani-specific MAb D2 by sera
from Indian VL patients before and after a single course of treatment with
pentavalent antimony. Group A, drug-responsive patients before (E) and after
(F) treatment; group B, drug-unresponsive patients before () and after ()
treatment. Sera were diluted 1:50 and assayed by C-ELISA as described in
Materials and Methods.
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smears) or SAG resistant (persistence of fever and hepato-
splenomegaly and/or absence of parasites).
The study included 57 of 110 (51.8%) SAG-responsive and
53 of 110 (48.2%) SAG-resistant patients. Groupwise, the dis-
tributions of SAG-responsive patients were 57.0, 48.6, and
52.0% in groups A, B, and C, respectively. Accordingly, the
distributions of SAG-unresponsive patients were 43.0, 51.4,
and 48.0% in groups A, B, and C, respectively (Table 1).
Cross-reactivity studies. Sera from patients with malaria,
tuberculosis, and leprosy as well as healthy controls from areas
of endemicity and nonendemicity were checked for cross-re-
activity by C-ELISA and ELISA. No false-positive results were
observed by either assay. The percent inhibition of MAb D2
binding with sera from healthy controls or patients with ma-
laria or leprosy ranged from 0 to 5% and ranged from 0 to 10%
for patients with tuberculosis (mean 6 SD 5 5.2% 6 1.8%).
No differences in MAb D2 inhibition were observed with con-
trol sera from patients from areas of endemicity and nonen-
demicity.
DISCUSSION
In this study with a large number of serum samples, we have
evaluated the potential of the C-ELISA as a diagnostic and
prognostic tool for the monitoring of patients with VL and
PKDL. Our results indicate that the C-ELISA with MAb D2 is
an extremely sensitive and specific tool for the screening of
patients with VL and PKDL. The C-ELISA is superior to
microscopic examination and is comparable to the direct
ELISA in detecting early parasite infections, especially in pa-
tients with fevers of short duration (group A) and intermediate
duration (group B), among whom it identified an additional
16.0 and 7.0% cases of VL, respectively (Table 2).
Because the presenting symptoms of VL, which include fe-
ver, progressive weight loss, hepatosplenomegaly, and hyper-
gammaglobulinemia, are common to other coendemic diseases
in India, clinicians often face a diagnostic dilemma. The readily
available serological tests for VL which use crude antigen
frequently show false-positive cross-reactions with other coen-
demic diseases. Therefore, it is essential to find sensitive, non-
invasive diagnostic methods which can specifically identify VL
early in the disease process. By the C-ELISA, cross-reactivity
with sera from Indian patients with other coendemic diseases,
such as malaria, tuberculosis, and leprosy, was not observed.
Longitudinal follow-up of VL patients revealed marked dif-
ferences in the percent inhibition of MAb D2 binding in the
drug-responsive and drug-unresponsive group before and after
a single course of treatment with SAG. With elimination of the
parasite, the drug-responsive group showed a significant de-
crease in the percent inhibition of MAb D2 (Fig. 2, group A).
However, in patients refractory to chemotherapy, the percent
inhibition of MAb D2 either was unchanged or was marginally
increased (Fig. 2, group B). Therefore, the C-ELISA indirectly
provides circumstantial evidence of the presence or absence of
circulating Leishmania parasite because the degree of inhibi-
tion of MAb D2 binding depends on the competition by patient
antibody for the parasite antigen epitope recognized by the
MAb.
In India, VL is generally assumed to be caused by L. dono-
vani, although in recent times L. tropica has been shown to
be a causative agent (18). Among four Indian patients with
L. tropica infection examined in their study, two were found to
be unresponsive to antimonial drugs. Likewise, patients with
VL caused by L. tropica in Kenya have also been reported to be
nonresponsive to SAG (14). The leishmanial species that cause
disease can be characterized either indirectly by culturing the
parasites from tissue aspirates or directly by PCR. The former
technique is frequently unsuccessful, is disliked by patients,
and requires culture of the parasite prior to analysis. The latter
technique is still expensive and requires sophisticated labora-
tory facilities and trained personnel. Unlike both of those
techniques, the C-ELISA with MAb D2 is simple, does not
require special equipment or training, is performed like a reg-
ular ELISA, and is suitable for epidemiological screening stud-
ies.
Previous studies have shown that MAb D2 is specific for the
L. donovani complex, does not cross-react with other Leishma-
nia species (12), and can be used to identify patients with VL
and PKDL (8, 10). The binding specificity of MAb T11 for
L. tropica (formerly L. tropica minor) has been demonstrated;
it specifically recognizes L. tropica isolates from both cutane-
ous leishmaniasis and VL patients and does not react with
other Leishmania species (11). In fact, this specificity of MAb
T11 has been exploited to characterize L. tropica isolates from
Indian VL patients (18). Since MAbs D2 and T11 only recog-
nize parasites belonging to either L. donovani or L. tropica and
do not cross-react with each other, they provide indirect iden-
tification of the leishmanial species causing the disease. Be-
cause the 110 serum samples from patients suspected of having
VL and 7 serum samples from patients with PKDL tested in
this study only inhibited MAb D2 binding, with negligible in-
hibition of MAb T11, our study indicates that L. donovani still
remains the main causative agent of Indian leishmaniasis.
The dramatic increase in unresponsiveness to conventional
antimony therapy in the ongoing epidemic has raised questions
as to whether an alteration in the causative Leishmania species
has a contributory role. Here we have reported on a high
incidence of unresponsiveness to antimonial agents, irrespec-
tive of the duration of illness (Table 1). However, sera from
none of the SAG-resistant patients showed any inhibition of
MAb T11 binding, suggesting that the refractoriness of VL
patients to SAG is not related to the appearance of L. tropica.
The humoral response, as measured by the percent inhibi-
tion of MAb D2 (C-ELISA) and antileishmanial antibody ti-
ters (ELISA), showed increases of 47.2 and 50.7% from a short
FIG. 3. Correlation between ELISA and percent inhibition of binding of
L. donovani-specific monoclonal MAb D2 by C-ELISA of sera from Indian VL
patients.
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duration of illness (group A) to an intermediate duration of
illness (group B), respectively (Fig. 1; Table 2). Smaller in-
creases in the inhibition of MAb D2 binding (22.8%) and
ELISA titers (19%) were seen in patients with a prolonged
duration of illness (group C) than in group B patients. Finally,
a positive correlation (r2 5 0.84) was found between individual
percent inhibition of MAb D2 binding and an increasing reac-
tion of antileishmanial antibodies as measured by ELISA (Fig.
2). Antileishmanial antibody titers measured by DAT have
been reported to remain positive for up to 5 years after recov-
ery in .50% of VL patients examined (16). Serological assays
for the diagnosis of VL in HIV-positive patients are known to
have a high incidence of false negativity, although rK39 has
shown promise both for the diagnosis and the monitoring of
patients with HIV infection and VL (7). Because the C-ELISA
has proved to be a sensitive indicator of the disease status for
the evaluation of disease progression and therapeutic effec-
tiveness, its role in patients with HIV infection and VL should
be assessed. Additionally, extension of the C-ELISA to sam-
ples from a larger population will provide evidence of its clin-
ical applicability; such studies are ongoing.
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